Request that the FDA grant permission to file an abbreviated new animal drug application (ANADA) for a generic soft chewable tablet for Graphiprant that differs from the pioneer product Galliprant (grapiprant tablets), sponsored by Elanco US Inc, under NADA 141-455
🏛 Food and Drug Administration (FDA)FDA-2026-P-5875
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.